Extract
Humbert et al. [1] report safety and efficacy results from the long-term open-label extension study of the phase 2 PULSAR placebo-controlled, randomised trial of sotatercept in pulmonary arterial hypertension (PAH) in this issue of the European Respiratory Journal. Subjects who had completed the phase 2, 24-week randomised trial were eligible for participation, with ex-placebo subjects re-randomised to receive sotatercept in doses of either 0.3 or 0.7 mg·kg−1, while ex-sotatercept subjects remained on their earlier randomised dose.
Abstract
Sotatercept is a drug that targets a novel pathogenic pathway in pulmonary arterial hypertension and has the potential to be an effective new therapy for this condition https://bit.ly/3s1tQb1
Footnotes
Conflict of interest: L.J. Rubin reports consultancy fees from Gossamer, Sonivie, Bellerophon and Drug-farm, and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Johnson & Johnson. R. Naeije reports payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Lung Biotechnology and AOP Orphan Pharmaceuticals, and participation on a data safety monitoring board or advisory board for Johnson & Johnson, AOP Pharmaceuticals, United Therapeutics and Lung Biotechnology.
- Received October 12, 2022.
- Accepted October 13, 2022.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org